Current clinical trials in retinoblastoma include:
EudraCT Number: 2011-006109-85 Sponsor Protocol Number: RTBAIEOP012 Start Date: 2012-02-14 Sponsor Name:
A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA Full Title:
DIAGNOSTIC AND THERAPEUTIC STUDY FOR NEWLY DIAGNOSED RETINOBLASTOMA PATIENTS RTB AIEOP 012
Medical condition:Newly diagnosed retinoblastoma patientsDisease: Version 14.1 SOC Term 10010331 - Congenital, familial and genetic disorders Classification Code 10038916 Term Retinoblastoma Level PT Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female Trial protocol: IT (Ongoing)Trial results: (No results available)
Clinical trial Number: NCT02329002 Full Title: Multicentric implementation of MR imaging in irradiated hereditary RB survivors
Objective:For the evaluation of the value of craniofacial MRI screening for early detection of second craniofacial primary tumours and to enhance survival Status:Not recruiting Prinicipal investigator Pim de Graaf
RB-Registry: clinical registry for prospective data on retinoblastoma epidemiology and clinical course Funded by Deutsche Kinderkrebsstiftung. Our aim with the RB-Registry is to gather epidemiological and clinical data on pediatric eye tumors to develop a knowledge base. The knowledge gathered within RB-Registry will improve counseling for newly diagnosed patients and will provide a base for the development of interventional clinical trials to improve early diagnosis, treatment and follow-up for retinoblastoma patients. RB-Registry provides a consultation hotline and reference evaluations. The database and a biobank will support accompanying biological studies. The long-term perspective of RB-Registry is to improve survival rates in advanced tumor stages to reduce late effects and improve the quality of life of survivors.
Inclusion criteria:Patients newly diagnosed with retinoblastoma or other pediatric eye tumors and children with newly diagnosed RB1 germline mutation who are residents of Germany and Austria and have not received prior treatment for retinoblastoma Objectives:The primary objective is to evaluate the exact retinoblastoma group (ICRB) and stage (IRSS) distribution in Germany and Austria Prinicpal Investigator: Dr Petra Temming
EudraCT Number: 2009-016448-38 Sponsor Protocol Number: IC 2009-04 Start Date: 2009-12-15 Sponsor Name:
Institut Curie Full Title:
Traitement adjuvant dans les rétinoblastomes unilatéraux étendus énucléés d’emblée.
Rétinoblastomes unilatéraux étendus énucléés d’emblée. Disease: Version 12.0 SOC Term Classification Code 10038916 Term Retinoblastoma Level LLT Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female Trial protocol: FR (Ongoing) Trial results: (No results available)
EudraCT Number: 2012-002825-31 Sponsor Protocol Number: : INTV-STC-RT-SI-2012 Start Date: 2012-07-01 Sponsor Name:
AZIENDA OSPEDALIERA SENESE Full Title:
NEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: INTRAVITREAL AND SUBCONJUNCITIVAL INJECTION OF CHEMOTHERAPY in the intraoculars RTBs
patients with RTB Disease: Version 14.1 SOC Term10015919 - Eye disorders Classification Code 10030054 Term Ocular neoplasms Level HLGT
Disease: Version 14.1 SOC Term10015919 - Eye disorders Classification Code 10015919 Term Eye disorders Level SOC Population Age:Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female Trial protocol: FR (Ongoing) Trial results: (No results available)
EudraCT Number: 2016-001060-11 Sponsor Protocol Number: : FSJD-RTB-2015 Start Date: 2017-08-03 Sponsor Name:Fundació Sant Joan de Déu Full Title:A Phase I, unicentric, open and dose escalation clinical trial to evaluate the safety and the activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma
Medical condition:refractory retinoblastoma Disease:Version 14.1 SOC Term10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) Classification Code 10038916 Term RetinoblastomaLevel PT
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.